These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32770730)

  • 1. Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
    Nelander K; Lagerstrom-Fermer M; Amilon C; Michaëlsson E; Heijer M; Kjaer M; Russell M; Han D; Lindstedt EL; Whatling C; Gan LM; Ericsson H
    Clin Transl Sci; 2021 May; 14(3):812-819. PubMed ID: 32770730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
    Gan LM; Lagerström-Fermér M; Ericsson H; Nelander K; Lindstedt EL; Michaëlsson E; Kjaer M; Heijer M; Whatling C; Fuhr R
    Br J Clin Pharmacol; 2019 Apr; 85(4):762-770. PubMed ID: 30618054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.
    Lam CSP; Lund LH; Shah SJ; Voors AA; Erlinge D; Saraste A; Pirazzi C; Grove EL; Barasa A; Schou M; Aziz A; Svedlund S; Wijngaarden JV; Lindstedt EL; Gustavsson A; Nelander K; Garkaviy P; Gan LM; Gabrielsen A
    J Card Fail; 2024 Jan; 30(1):104-110. PubMed ID: 37072105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
    Inghardt T; Antonsson T; Ericsson C; Hovdal D; Johannesson P; Johansson C; Jurva U; Kajanus J; Kull B; Michaëlsson E; Pettersen A; Sjögren T; Sörensen H; Westerlund K; Lindstedt EL
    J Med Chem; 2022 Sep; 65(17):11485-11496. PubMed ID: 36005476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
    Bhattacharya C; Sandinge AS; Bragg RA; Heijer M; Yan J; Andersson LC; Jurva U; Pelay-Gimeno M; Vaes WHJ; de Ligt RAF; Gränfors M; Amilon C; Lindstedt EL; Menakuru SR; Garkaviy P; Weidolf L; Gopaul VS
    Drug Metab Dispos; 2023 Apr; 51(4):451-463. PubMed ID: 36639243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S; Boy M; Chow V; Chan G
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.
    Kanodia J; Lo A; Baldwin RM; Colley K; Zhou K; Bourdet DL
    Clin Transl Sci; 2020 Nov; 13(6):1307-1315. PubMed ID: 32506827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF.
    Michaëlsson E; Lund LH; Hage C; Shah SJ; Voors AA; Saraste A; Redfors B; Grove EL; Barasa A; Richards AM; Svedlund S; Lagerström-Fermér M; Gabrielsen A; Garkaviy P; Gan LM; Lam CSP
    JACC Heart Fail; 2023 Jul; 11(7):775-787. PubMed ID: 37140510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
    van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
    J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
    Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
    Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.
    Parkinson J; Sundell J; Rekić D; Nelander K; Ericsson H; Ebrahimi A; Dota C; Sunnåker M
    Pharmacol Res Perspect; 2024 Apr; 12(2):e1184. PubMed ID: 38445541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
    van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects.
    Sunwoo J; Oh J; Moon SJ; Ji SC; Lee SH; Yu KS; Kim HS; Lee A; Jang IJ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):206-218. PubMed ID: 29863280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
    Kim BH; Lim HS; Chung JY; Kim JR; Lim KS; Sohn DR; Cho JY; Yu KS; Shin SG; Paick JS; Jang IJ
    Br J Clin Pharmacol; 2008 Jun; 65(6):848-54. PubMed ID: 18318773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.